Gemtesa Shortage Update: What Patients Need to Know in 2026

If you've been searching online for a "Gemtesa shortage 2026" — you're not alone. Many patients with overactive bladder (OAB) are searching for information after struggling to fill their vibegron prescription. This post gives you the most current information on Gemtesa's availability status.

Is There a Gemtesa Shortage in 2026?

As of 2026, Gemtesa (vibegron) is NOT listed on the FDA's official drug shortage database. This means there is no declared national supply interruption from the manufacturer, Sumitomo Pharma America. The drug is being manufactured and distributed.

However, many patients still report difficulties getting it filled at their local pharmacy. This is a different problem from a shortage — and it requires a different solution.

Why Do Patients Still Have Trouble Filling Gemtesa?

There are four main reasons patients experience Gemtesa access problems even without a formal shortage:

Pharmacy stocking gaps. Gemtesa is a brand-only drug with a high retail price. Not all pharmacies keep it on their shelves, especially in smaller towns and rural areas.

Insurance prior authorization. Many plans require PA review before covering Gemtesa, which can delay access for days or weeks.

Step therapy requirements. Some insurance plans require patients to try and fail cheaper OAB medications before approving Gemtesa.

Cost without coverage. At $612–$692 per month without insurance, many patients simply cannot afford refills consistently.

Historical Supply Context

Gemtesa was first FDA-approved in December 2020 and commercially launched in the U.S. in April 2021. The drug has no history of an FDA-declared shortage since its launch. It has steadily grown in market share, with projected U.S. sales exceeding $1 billion by 2027. In December 2024, the FDA expanded its approval to include men with OAB being treated for BPH — further expanding its patient base.

The drug's supply chain has remained stable through Sumitomo Pharma America. There are no known manufacturing disruptions, recalls, or import alerts associated with Gemtesa.

What to Do If You Can't Get Gemtesa

Even without a formal shortage, access problems are real. Here's your action plan:

Find it faster with medfinder. medfinder calls pharmacies near you to find which ones have your medication in stock, then texts you the results — no hold music required.

Use the savings program. Commercially insured patients with coverage can pay as little as $10/month with the Gemtesa Simple Savings Program. Text GEMTESA to 436872 to enroll.

Ask your doctor to fight the PA. If your insurer denied coverage, your doctor can submit documentation explaining why Gemtesa is medically necessary, or appeal the decision.

Consider a 90-day mail-order supply. Mail-order pharmacies maintain more consistent inventory and often offer lower per-dose pricing on 90-day supplies.

Discuss alternatives. If access remains impossible, see Alternatives to Gemtesa for a full comparison.

The Bottom Line on Gemtesa in 2026

Gemtesa is not in shortage. Its supply chain is stable and the manufacturer is not reporting production issues. If you're having trouble filling it, the problem is almost certainly related to your pharmacy's stock levels, your insurance coverage situation, or cost — all of which have solutions. Take those steps above and you'll be able to get back on your medication.